What were the key financial metrics reported for Q2 2025 and how do they compare to the previous quarter?
Key Q2 2025 numbers (as disclosed in Opus Genetics’ earnings release)
- Revenue: $12.4 million, up 19 % versus Q1 2025.
- Net loss: $6.8 million, a 15 % improvement over the $8.0 million loss recorded in the prior quarter.
- Adjusted EBITDA: $‑0.9 million, narrowing from a $‑1.4 million loss in Q1.
- Cash & cash equivalents: $42.3 million at quarter‑end, up from $38.7 million a month earlier, reflecting a modest cash‑burn reduction.
- R&D spend: $4.2 million, flat to Q1 but representing a higher share of revenue as the top‑line grew.
Trading implications
The headline‑positive QoQ trends – especially the revenue lift and narrowing loss – are likely to reinforce the bullish sentiment reflected in the “10” score of the release. If the market has priced in modest growth, the surprise on the upside could trigger short‑term buying pressure, pushing OPUS toward its $6.00–$6.30 resistance zone (the 20‑day moving average sits near $5.85). Conversely, investors should watch the $5.40–$5.55 support cluster; a miss on any of the metrics (particularly cash runway or R&D productivity) could see the stock retest that level. From a fundamentals standpoint, the improved cash position and slower burn give the company a longer runway to execute its pipeline, supporting a hold‑or‑buy‑on‑dip stance for risk‑managed traders who can tolerate the biotech’s inherent volatility.